From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today announced the presentation of new preclinical data ...

Depletion of NK cells was local to the tumor microenvironment, as splenic and peripheral NK cells were unaffected. The same AK-5 tumor cells did not express FasL when injected subcutaneously.

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

Pilatus Biosciences, a biotechnology company developing immunometabolic therapies for cancer, today announced a preclinical publication in Cancer Discovery detailing the mechanism and therapeutic ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell ...

LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland ...

Microbiotica’s MB097, an oral microbiome-based therapy, shows promise in boosting immunotherapy response in melanoma patients ...

The challenges in the field of CAR-NK cell engineering and design for cancer patients encompass issues related to manufacturing, clinical application, immunosuppressive tumor microenvironment (solid ...

Natural killer cells aren't just mindless defenders — a special type, adaptive NK cells, remember their enemies and come back ...